Utility of novel androgen receptor therapies in the real world: A nuanced approach

Urol Oncol. 2016 Aug;34(8):340-7. doi: 10.1016/j.urolonc.2016.05.002. Epub 2016 Jul 21.

Abstract

Abiraterone and enzalutamide are in widespread clinical use because of their favorable safety and efficacy. Nonetheless, even with newer agents, resistance develops overtime. In this review, we discuss mechanisms of resistance to these newer agents as well as novel therapeutic agents. We also review the literature to help clinicians decide which agent to begin with and when to stop or switch androgen receptor agents.

Keywords: Androgen receptor therapies; Novel therapies; Prostate cancer; Resistance mechanisms.

Publication types

  • Review

MeSH terms

  • Androgen Antagonists / therapeutic use*
  • Androgen Receptor Antagonists / therapeutic use*
  • Androstenes / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Benzamides
  • Clinical Trials as Topic
  • Drug Resistance, Neoplasm
  • Humans
  • Male
  • Nitriles
  • Phenylthiohydantoin / analogs & derivatives*
  • Phenylthiohydantoin / therapeutic use
  • Prostatic Neoplasms, Castration-Resistant / drug therapy*
  • Receptors, Androgen

Substances

  • Androgen Antagonists
  • Androgen Receptor Antagonists
  • Androstenes
  • Antineoplastic Agents
  • Benzamides
  • Nitriles
  • Receptors, Androgen
  • Phenylthiohydantoin
  • enzalutamide
  • abiraterone